Tag Archive

Advaxis’s HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma

In Press Release by CameronMay 27, 2014Leave a Comment

Clinical development program in pediatric osteosarcoma will leverage orphan drug status. May 27, 2014 Advaxis, Inc., a leader in developing cancer immunotherapies, announced that …

Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer

In Press Release by CameronMay 6, 2014Leave a Comment

Clinical data in canine osteosarcoma presented at sarcoma foundation of America annual Conference. May 5, 2014 Advaxis, Inc., a biotechnology company developing cancer immunotherapies, announced it …

[[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

[[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

Choosing the Right Channel Strategy for Specialty Product Success

[Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

[[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

Tag Archive

Advaxis’s HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma

Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer

Categories